Table 5 Studies on definitive radiotherapy with or without chemotherapy for oesophageal cancer patients
Study | Type | Pathology | Stage | N | Treatment (n) | Radiation dose (Gy) | Chemotherapy regimen | ORR | MST (month) | 1 year OS | 3 year OS | 5 year OS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Herskovic A, 1992 [7]; al-Sarraf M, 1997 [8]; Cooper JS, 1999 [6] | Prospective Randomized (RTOG 85 − 01) | Sq/Ad | T1-3 N0-1 M0 | 123 | RT alone (62) | 64 | / | / | 9.3 | 34% | 0% | 0% |
RT + CT (PF) (61) | 50 | CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d4, Q4W | / | 14.1 | 52% | 30% | 26% | |||||
Minsky BD, 1996 [30]; Minsky BD, 1999 [31]; | Prospective (INT 0122) | Sq | T1-4 N0-1 M0 | 38 | CT (PF) → RT + CT (PF) (38) | 64.8 | Neoadjuvant segment: CDDP 100 mg/m2 d1 + 5-FU 1 g/m2/d d1-d5, Q4W; Combined segment: CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d5, Q4W | 55% | 20 | / | 30% | 20% |
Atsushi Ohtsu, 1999 [32] | Prospective | Sq | T4/M1 LYM | 54 | RT + CT (PF) (54) | 60 | CDDP 40 mg/m2 d1, d8 + 5-FU 400 mg/m2/d d1-d5, d8-d12, Q5W | 87% | 9 | 41% | 23% | / |
Minsky BD, 2002 [5] | Prospective (INT 0123) (RTOG 94 − 05) | Sq/Ad | T1-4 N0-1 M0 | 218 | RT + CT (PF) (109) | 50.4 | CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d4, Q4W | / | 18.1 | 40% | / | / |
|  |  |  |  |  | RT + CT (PF) (109) | 64 | CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d4, Q4W | / | 13 | 31% | / | / |
Ishida K, 2004 [33] | Prospective | Sq | T4/M1 LYM | 60 | RT + CT (PF) (60) | 60 | CDDP 70 mg/m2 d1 + 5-FU 700 mg/m2/d d1-d4, Q4W | 68.3% | 10 | / | / | / |
Ajani JA, 2008 [34] | Prospective randomized (RTOG 0113) | Sq/Ad | Localized | 72 | CT(TPF) → RT + CT (TF) (37) | 50.4 | / |  | 28.7 | 75.7% |  |  |
CT(TP) → RT + CT (TP) (35) | 50.4 | / |  | 14.9 | 68.6% |  |  | |||||
Li QQ, 2010 [17] | Retrospective | Sq | II - IV | 59 | RT + CT (DP) (59) | 50–64 | CDDP 80 mg/m2 d1 + Docetaxel 60 mg/m2 d1, Q3W | 98.3% | 22.6 | / | 36.7% | / |
Kato K, 2011 [35] | Prospective (JCOG 9906) | Sq | II - III | 74 | RT + CT (PF) (74) | 60 | CDDP 40 mg/m2 d1, d8 +  5-FU 400 mg/m2/d d1-d5, d8-d12, Q5W | 66.2% | 29 | / | 44.7% | / |
Nishimura Y, 2012 [36] | Prospective (KROSG0101/ JROSG021) | Sq/Ad | II - IV | 91 | RT + CT (PF) (46) | 60 | CDDP 70 mg/m2 d1 + 5-FU 700 mg/m2/d d1-d5, Q4W | / | / | / | / | 35% |
RT + CT (PF) (45) | 60 | CDDP 7 mg/m2 d1-d5, d8-d12 + 5-FU 250 mg/m2/d d1-d14, Q4W | / | / | 44% | 22% | 71% | |||||
Zhao T, 2012 [16] | Prospective | Sq | II - IV | 90 | RT + CT (PF) (45) | 50.4 | CDDP 75 mg/m2 d1 + 5-FU 250 mg/m2/d d1-d4, Q4W | 53.3% | 22.3 | / | / | / |
RT + CT (DP) (45) | 50.4 | CDDP 75 mg/m2 d1 + Docetaxel 75 mg/m2 d1, Q4W | 73.3% | 43.2 | / | / | / | |||||
Conroy T, 2014 [3] | Prospective (PRODIGE5/ ACCORD17) | Sq/Ad | I - IV | 267 | RT + CT (FOLFOX) (134) | 50 | / | 67% | 20.2 |  | 19.9% |  |
RT + CT (PF) (133) | 50 | CDDP 75 mg/m2 d1 + 5-FU 1 g/m2/d d1-d4, Q3W/Q4W | 65% | 17.5 |  | 26.9% |  | |||||
Zhang P, 2016 [37] | Prospective | Sq | II - IV | 317 | RT + CT (PF) (156) | 50–70 | CDDP 60 mg/m2 d1 + 5-FU 300 g/m2 d1-d3, Q4W | / | 24 | 77.4% | 32.8% | / |
RT + CT (DP) (161) | 50–70 | CDDP 80 mg/m2 d1 + Docetaxel 60 mg/m2 d1, Q3W; OR CDDP 25 mg/m2 d1 + Docetaxel 25 mg/m2 d1, QW | / | 21 |  |  |  | |||||
Dashan Ai, 2022 [10] | Prospective (ESO-Shanghai2) | Sq | II - IV | 321 | RT + CT (TP) (107) | 61.2 | CDDP 25 mg/m2/d d1-d3 + Paclitaxel 175 mg/m2 d1, Q4W | / | / | 81.3% | 60.1% | / |
RT + CT (TF) (107) | / | / | / | 79.4% | 57.2% | / | ||||||
RT + CT (TC) (107) | / | / | / | 79.4% | 56.5% | / | ||||||
Current study | Prospective | Sq | II - IV | 86 | RT + CT (DP) (45) | 55.8–64.0 | CDDP 80 mg/m2 d1 + Docetaxel 60 mg/m2 d1, Q3W | 84.4% | 42.27 | 87.3% | 59.5% | 52.7% |
RT + CT (PF) (41) | 56.0–64.0 | CDDP 80 mg/m2 d1 + 5-FU 1000 g/m2 d1-d4, Q3W | 87.8% | Not reached | 93.7% | 65.5% | 62.9% |